Please try another search
Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents, such as Riona for the treatment of hyperphosphatemia; and REMITCH, an oral therapeutic agent for the treatment of pruritus in dialysis and liver disease patients. The company also provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; CORECTIM, a topical janus kinase (JAK) inhibitor; and allergen immunotherapy tablets comprising CEDARCURE and MITICURE. In addition, it is engaged in real estate rental business. The company markets its products primarily through medical representatives for medical professionals. The company has a collaboaration with ALK-Abelló A/S to develop, market and distribute ALK's allergy immunotherapy tablet for the treatment of grass pollen allergy. The company was formerly known as Torii Shoten K.K and changed its name to Torii Pharmaceutical Co., Ltd. in May 1949. The company was founded in 1872 and is headquartered in Tokyo, Japan. Torii Pharmaceutical Co., Ltd. is a subsidiary of Japan Tobacco Inc.
Name | Age | Since | Title |
---|---|---|---|
Goichi Matsuda | - | 2019 | President, CEO & Representative Director |
Eiichi Izumo | - | 2016 | Outside Member of Audit & Supervisory Board |
Ken Yamamoto | - | 2018 | Member of Standing Audit & Supervisory Board |
Takaharu Matsumura | 53 | 2018 | Outside Member of Audit & Supervisory Board |
Toshio Fukuoka | 69 | 2016 | Independent Outside Director |
Masao Torikai | 60 | - | Independent Outside Director |
Nobumasa Kondo | 55 | 2019 | Managing Executive Officer & Planning and Support Group Leader |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review